secwatch.observer — SEC 8-K summary
======================================

Issuer:     RAPT Therapeutics, Inc. (—)
CIK:        0001673772
Form:       8-K
Filed at:   2026-01-20T23:59:59+00:00
Accession:  0001193125-26-015882
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RAPT Therapeutics to be acquired by GSK for $58/share in all-cash tender offer
------------------------------------------------------------------------------

- GSK subsidiary will commence tender offer at $58.00 per share in cash within 10 business days.
- Company termination fee set at $78.4M; reverse termination fee payable by GSK at $100.8M.
- Support agreements cover ~0.25% of outstanding shares; Board recommends tender.
- Transaction expected to close by July 19, 2026, subject to HSR clearance and majority tender condition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1673772/000119312526015882/0001193125-26-015882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1673772/000119312526015882/d12800d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-015882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer